Working… Menu

Role of Enhanced External Counterpulsation (EECP) Therapy in Patients With Resistant Hypertension (EECP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00953797
Recruitment Status : Withdrawn
First Posted : August 6, 2009
Last Update Posted : January 26, 2012
Information provided by (Responsible Party):
Darshak Karia, MD, Albert Einstein Healthcare Network

Brief Summary:

High Blood Pressure or Hypertension is one of the main causes of stroke, heart disease, heart attack and kidney disease. Traditionally physicians use diet and lifestyles change and medications to control patient's blood pressure. There are however, some patients whose blood pressures are difficult to control and their blood pressure remains elevated despite multiple medications. When blood pressure remains above goal (greater then 140/90 or greater then 130/80 mmHg in patients with diabetes or kidney disease) despite 3 or more blood pressure medications, the investigators call it "Resistant Hypertension".

Enhanced External Counterpulsation (EECP) is a new method of treatment currently used in people with heart disease and chest pain. EECP therapy uses three sets of balloon like cuffs that are wrapped to the calves, lower thighs, and upper thighs. These cuffs inflate and deflate with every heart beat, causing increased blood return to the heart and better blood flow. It has also been found to improve the function of endothelial cells, a type of cells that lines the wall of blood vessel through out the body which helps to regulate and maintain blood pressure. This leads us to believe that EECP therapy, although not used at present for treating patients with Resistant Hypertension, may be useful in decreasing blood pressure.

Condition or disease Intervention/treatment Phase
Hypertension Device: Enhanced External Counterpulsation Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Role of EECP Therapy in Patients With Resistant Hypertension
Study Start Date : May 2009
Actual Primary Completion Date : October 2011
Actual Study Completion Date : October 2011

Resource links provided by the National Library of Medicine

Intervention Details:
  • Device: Enhanced External Counterpulsation
    A non-invasive method currently used for the treatment of ischemic coronary disease. During EECP therapy three compressive pneumatic cuffs are wrapped around the calves, lower thighs, and upper thighs. The cuffs inflate sequentially during diastole causing retrograde aortic flow, and increased venous return. At end diastole, the cuffs rapidly deflate resulting in unloading of the left ventricle and a decrease in systolic blood pressure.

Primary Outcome Measures :
  1. Change from baseline in mean ambulatory 24-hour systolic ambulatory blood pressure [ Time Frame: Approximately 50 days ]

Secondary Outcome Measures :
  1. Change from baseline in mean ambulatory 24-hour diastolic ambulatory blood pressure [ Time Frame: Approximately 50 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects who are competent to provide written consent
  • Aged 18 to 80 years
  • Deemed to be compliant with anti-hypertension medication therapy.
  • Subjects with diabetes and/or chronic kidney disease must have a mean systolic blood pressure ≥130 mmHg
  • All other subjects must have a mean systolic blood pressure ≥140 mmHg
  • Receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic
  • Female subjects of non-childbearing potential (i.e., post-menopausal for at least 2 years; surgically sterile)
  • Deemed to be compliant with anti-hypertension medication therapy

Exclusion Criteria:

  • Average sitting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg
  • Known Sleep apnea
  • Subjects who have participated in a clinical study involving another investigational drug or device within 4 weeks prior to Screening
  • Have hypertension secondary to an identifiable and treatable cause other than sleep apnea
  • Acute coronary syndrome < 6 weeks prior to enrollment
  • Non-bypassable left main coronary with a luminal stenosis ≥ 50%
  • CABG < 3 months or PCI < 6 months prior to enrollment
  • Cardiac catheterization < 2 weeks prior to enrollment
  • Arrhythmias that would significantly interfere with the triggering of the EECP device.
  • Clinically significant valvular heart disease
  • Acute myocarditis
  • ICD if it has been triggered < 3 months prior to enrollment
  • History of deep vein thrombosis, phlebitis, stasis ulcer, pulmonary embolism, and/or aortic aneurysm
  • INR ≥ 2.5
  • Patients taking over the counter medications that can raise blood pressure, such as

    • Non narcotic analgesics
    • Non steroidal anti-inflammatory agents, including aspirin, Selective COX-2 inhibitors
    • Sympathomimetic agents (decongestants, diet pills, cocaine)
    • Stimulants (methylphenidate, dexmethylphenidate, dextroamphetamine, amphetamine, methamphetamine, modafinil)
    • Alcohol
    • Oral contraceptives
    • Cyclosporine
    • Erythropoietin
    • Natural licorice
    • Herbal compounds (ephedra or ma huang)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00953797

Layout table for location information
United States, Pennsylvania
Albert Einstein Medical Center
Philadelphia, Pennsylvania, United States, 19141
Sponsors and Collaborators
Albert Einstein Healthcare Network
Layout table for investigator information
Principal Investigator: Darshak H Karia, MD Albert Einstein Medical Center
Layout table for additonal information
Responsible Party: Darshak Karia, MD, Director of Heart Failure Services, Albert Einstein Healthcare Network Identifier: NCT00953797    
Other Study ID Numbers: HN4112
First Posted: August 6, 2009    Key Record Dates
Last Update Posted: January 26, 2012
Last Verified: January 2012
Keywords provided by Darshak Karia, MD, Albert Einstein Healthcare Network:
Resistant Hypertension
Endothelial dysfunction
Enhanced External Counterpulsation
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases